Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 15/3/2021
SIETES contiene 93212 citas

 1 a 20 de 265 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Montastruc J-L. A propos du Levothyrox® : les réflexions du pharmacologue médical. 2017;24:60. [Ref.ID 102182]
2. Cita con resumen
3. Cita con resumen
Chekroud AM, Krystal JH. Personalised pharmacotherapy: an interim solution for antidepressant treatment?. BMJ 2015;350:h2502. [Ref.ID 99115]
5.Tiene citas relacionadas Cita con resumen
Steinberg BA. Refined bleeding estimates in adults starting anticoagulants. BMJ 2014;349:g4800. [Ref.ID 98176]
6. Cita con resumen
Torjesen I. Personalised medicine trial in lung cancer heralds new partnership. BMJ 2014;348:g2837. [Ref.ID 97965]
8. Cita con resumen
Wright DFB, Al-Sallami HS, Duffull SB. Is the dose of dabigatran really more predictable than warfarin?. Br J Clin Pharmacol 2013;76:997-8. [Ref.ID 96634]
9. Cita con resumen
van den Bemt BJF, den Broeder AA, Wolbink G-J, van den Maas A, Hekster YA, van Riel PLCM, Benraad HB, van den hoogen FHJ. The combined use of disease activity and infliximab serum trough concentrations for early prediction of (non-)response to infliximab in rheumatoid arthritis. Br J Clin Pharmacol 2013;76:939-45. [Ref.ID 96632]
10. Cita con resumen
Hermann HC. Who will do well on warfarin? Does it matter?. Journal Watch Cardiology Alert 2013:19 de junio. [Ref.ID 95636]
11.Tiene citas relacionadas Cita con resumen
Rane A, Ekström L. Androgens and doping tests: genetic variation and pit-falls. Br J Clin Pharmacol 2012;74:3-15. [Ref.ID 93372]
12.Tiene citas relacionadas
Ritter JM. Sex, steroids and anabolic androgens in athletics. Br J Clin Pharmacol 2012;74:1-2. [Ref.ID 93371]
14. Cita con resumen
Anónimo. Saquinavir: update on potential risk of arrhythmia - reduced dose for initial treatment. Drug Safety Update 2010;4:diciembre. [Ref.ID 89524]
15. Cita con resumen
Anónimo. Canadian doctors advise phasing out codeine. BMJ 2010;341:798. [Ref.ID 89510]
16.Tiene citas relacionadas Cita con resumen
Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann F-J, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. A meta-analysis. JAMA 2010;304:1821-30. [Ref.ID 89227]
17.Tiene citas relacionadas Cita con resumen
Fuster V, Sweeny JM. Clopidogrel and the reduced-function CYP2C19 genetic variant. JAMA 2010;304:1839-8140. [Ref.ID 89226]
18.Tiene citas relacionadas
Rothwell PM. ß blockers in hypertension. Author's reply. Lancet 2010;376:415-6. [Ref.ID 89073]
19.Tiene citas relacionadas
Cruickshank JM. ß blockers in hypertension. Lancet 2010;376:415. [Ref.ID 89072]
20. Cita con resumen
Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. Contraception 2010;81:474-80. [Ref.ID 88593]
Seleccionar todas
 1 a 20 de 265 siguiente >>